CARIPRAZINE
Information current as at: 1 December 2024
Submission Details
- Brand name:
-
- Reagila®
- Pharmaceutical company:
- Seqirus (Australia) Pty Ltd
- Condition/indication:
(therapeutic use) -
- Schizophrenia
- PBAC Submission type:
- New listing (Major submission)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – November 2020
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2020 PBAC meeting
-
Opportunity for consumer comment: - Open 26/08/2020 and close 07/10/2020 (see PBS Website)
-
PBAC meeting: - Held on 04/11/2020
-
Lodgement of required documentation: - 14/12/2020
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 24/12/2020
-
Status:
- Finalised
-
Government processes: - Commenced on 20/04/2021
-
Medicine listed on the PBS: - 01/09/2021 (see PBS schedule)
Case ID: a231
Page last updated: 31 October 2024